– 75% of patients with secondary progressive multiple sclerosis (SPMS) and primary progressive MS (PPMS) achieved no evidence of progression (NEP) in a one-year interim analysis of CONSONANCE study – ...

Roche’s multiple sclerosis superstar Ocrevus has run into few obstacles on its path to nearly $1 billion in global sales this year. Now, one major obstacle on the drug's blockbuster journey—England's ...

Roche Holding AG (OTCQX:RHHBY, OTCPK:RHHVF, OTCQX:RHHBF) is a good long-term biotech to own. That's because it already has received FDA approval for its multiple sclerosis [MS] drug OCREVUS. This drug ...

Multiple sclerosis is an inflammatory autoimmune disease, meaning the body attacks itself. The damage plays out in the central nervous system (brain and spinal cord), where the nerve endings and the ...

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), announced today that the U.S. Food and Drug Administration (FDA) approved OCREVUS™ ...

The U.S. Food and Drug Administration (FDA) approved Roche Holding AG’s multiple sclerosis (MS) drug Ocrevus Tuesday, making it the first U.S.-approved medicine for the primary progressive form of the ...

Roche’s much-anticipated multiple sclerosis drug ocrelizumab trounced a standard treatment, Rebif, in a new analysis of Phase III data, adding to competitive stats that could prove an edge in the ...

The post-hoc analyses found Ocrevus to significantly decrease disease activity and disability progression in patients with RMS and PPMS, as assessed by No Evidence of Progression or Active Disease ...

Results from the Phase III study showed that subcutaneous (SC) injection was consistent with IV infusion and demonstrated near-complete suppression of relapse activity (97%) and MRI lesions (97.2%) ...

Genentech is "bucking a trend" by charging less for its multiple sclerosis (MS) drug despite at least equal efficacy to others and improved safety, neurologist Michael Racke told BioWorld Today, ...

The Food and Drug Administration approved a new drug to treat multiple sclerosis Tuesday. The drug, called Ocrevus, is approved for use against the most common form of MS – the relapsing-remitting ...

– Results from the Phase III study showed that subcutaneous (SC) injection was consistent with IV infusion and demonstrated near-complete suppression of relapse activity (97%) and MRI lesions (97.2%) ...